Garlic

drug
On this page

Also known as Ae-garlicAllii bulbusAllii sativi bulbusAllium arenarium bulbAllium controversum bulbAllium longicuspis bulbAllium ophioscorodon bulbAllium pekinense bulbAllium sativumAllium sativum (garlic) bulb powderAllium sativum bulbAllium sativum bulb extractAllium sativum bulb powderAllium sativum extractAllium sativum ophioscorodonAllium sativum powderAllium sativum wholeB1233Cultivated garlic wholeDasuan

Summary

Garlic (CHEMBL2108463) is a phase-3 clinical-stage unknown; indicated across 4 conditions including alopecia areata and denture stomatitis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 4 conditions
  • Clinical trials: 18

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108463
NameGarlic
TypeUnknown
Max phase3

Also known as: Ae-garlic, Allii bulbus, Allii sativi bulbus, Allium arenarium bulb, Allium controversum bulb, Allium longicuspis bulb, Allium ophioscorodon bulb, Allium pekinense bulb, Allium sativum, Allium sativum (garlic) bulb powder, Allium sativum bulb, Allium sativum bulb extract

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
alopecia areata3MONDO:0005340EFO:0004192
denture stomatitis2MONDO:0006723EFO:1000893
follicular lymphoma2MONDO:0018906MONDO:0018906

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

PhaseTrials
Not specified14
PHASE41
PHASE31
PHASE2/PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00499460PHASE4COMPLETEDEffects of Garlic Supplements on Opioids in Healthy Volunteers
NCT02691117PHASE3TERMINATEDTopical Garlic Concentrate for Alopecia Areata in Children
NCT05050071PHASE2/PHASE3COMPLETEDEvaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth
NCT01198223PHASE2COMPLETEDEffect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis
NCT00079170Not specifiedCOMPLETEDDocetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00122889Not specifiedCOMPLETEDEffects of Garlic Supplements on Drug Metabolism
NCT01293591Not specifiedCOMPLETEDGarlic Intake And Biomarkers Of Cancer Risk
NCT01948453Not specifiedCOMPLETEDEffect of Garlic Tablet Some Indicators Related to Atherosclerosis
NCT02322541Not specifiedWITHDRAWNDietary Absorption of Garlic Metabolites Following Garlic Consumption
NCT03125551Not specifiedWITHDRAWNROTEM and Dietary Supplements
NCT03795636Not specifiedCOMPLETEDAllium Sativum Extract as an Irrigant
NCT04646382Not specifiedCOMPLETEDEffect of a Mixture of Allium Extracts on LDL Cholesterol Levels Volunteers With Elevated LDL Cholesterol Levels
NCT04647071Not specifiedCOMPLETEDAllium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers
NCT05016999Not specifiedCOMPLETEDAllium Extracts on the Intestinal Microbiota in Healthy Resident Volunteers.
NCT05082350Not specifiedUNKNOWNNutritional Intervention With Black Garlic
NCT05349253Not specifiedCOMPLETEDEffect of Garlic Extracts on Changes in Cerebral Blood Flow
NCT05349604Not specifiedCOMPLETEDEffect of Garlic Extracts on Changes in Blood Flow Velocity in the Carotid Artery
NCT05744752Not specifiedUNKNOWNEffects of Allium Sativum and Moringa Oleifera Extract on Dental Enamel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).